Abstract
Introduction Sierra Leone is one of the 30 high TB burden countries, with an incidence rate in 2023 of 286 per 100,000 population. Despite progress in case notification and treatment coverage, around 5,000 cases of TB in Sierra Leone are missing each year. Challenges with notification of drug-susceptible TB can result in drug-resistant TB. The COVID-19 pandemic has further compounded these challenges, resulting in increased drug-resistant TB cases and poor treatment outcomes. This study highlights the effect of COVID-19 on drug-resistant TB treatment outcomes. Methods We conducted a cross-sectional retrospective analysis of newly identified drug-resistant TB cases in Sierra Leone using data from the national drug-resistant TB database from January 2017 to December 2022, pre-COVID-19, during COVID-19, and post-COVID-19. Data was analysed using STATA. Descriptive analysis was used to summarise the demographic and clinical characteristics and treatment outcomes of drug-resitant TB cases. We used logistic regression to examine the association between time-period and treatment outcomes, after adjusting for age, gender, nutritional status, HIV status and treatment regimens. A p-value of <0.05 was considered statistically significant at 95% confidence level. Results Of the 701 drug-resistant TB patients, 383 (54.6%) were registered in the pre-COVID-19 period, 228 (32.5%) during COVID-19, and 92 (12.8%) in the post-COVID-19 period. Pre-treatment TB cases reduced from 359 (92.5%) in the pre-COVID-19 period to 80 (30.9%) in the COVID-19 period. New treatment cases increased from 29 (7.5%) to 159 (61.4%) during COVID-19. The proportion of drug-resistant TB that completed treatment decreased from 74.7% in the pre-COVID-19 period to 63.3% during COVID-19 and 68.5% post-COVID-19. There were more cases of successful treatment outcomes in the pre-COVID-19 period (74.7%) than in the COVID-19 period (63.3%). Compared with the pre-COVID-19 period, the odds of a successful outcome were 42% less than in the COVID-19 period (OR 0.58, 95% CI 0.42 to 0.82). Conclusion We reported a decline in the proportion of drug-resistant TB cases with successful treatment outcomes during COVID-19 and a rapid recovery in the post-COVID-19 period, emphasising the need for robust mitigation strategies for drug-resistant TB management during public health emergencies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Canadian Institutes for Health Research (CIHR) through an Operating Grant (WI1-179883) Addressing the Health Impacts of COVID-19. SM is funded by a Tier 2 Canada Research Chair in Mathematical Modeling and Program Science (CRC File Number 950-232643). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Sierra Leone Ethics and Scientific Review Committee with approval number 017/05/2023. Routine data was abstracted under a waiver of informed consent from the ethics committee and approval from the health facility management. The authors did not have access to information that could identify individual participants during or after data collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos